Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

NCT02035813 is registered in ClinicalTrials.gov with Prof. Wolfgang Janni as lead sponsor.

NCT NCT02035813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02035813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Lead sponsor
Prof. Wolfgang Janni
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2014
Completion date
January 10, 2024
Enrollment
116 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative and hormone-receptor positive metastatic breast cancer, her2-negative circulating tumor cells, postmenopausal female patients